Storia in 3 fonti

Novo Nordisk shares slump after drug failure in Alzheimer’s trial

Outcome is blow to one of Europe’s largest listed companies

Raccontata da

cnbc.com

ft.com

forbes.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

ft.comStai leggendo7 mesi fa

Novo Nordisk shares slump after drug failure in Alzheimer’s trial

Outcome is blow to one of Europe’s largest listed companies

originale

forbes.com7 mesi fa

Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.

Leggi questa versione → originale

Timeline cronologica

lunedì 24 novembre 2025·cnbc.com
Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
lunedì 24 novembre 2025·ft.com
Bayer soars on promising trial results for stroke prevention drug
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges

Novo Nordisk shares slump after drug failure in Alzheimer’s trial

Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails

Timeline cronologica

Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

Bayer soars on promising trial results for stroke prevention drug

Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

Novo Nordisk shares slump after drug failure in Alzheimer’s trial

Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails

New Novo drug delivers significant weight-loss benefits in diabetes trial